Lignocaine/ Lidocaine Market Information: By Application (Local Anesthesia, Anti-Arrhythmic), By Formulation (Injectable, Topical, Inhalation), By End User (Hospitals & Clinics, Dentist, Academia and Research Institutes) - Asia Pacific Forecast till 2030

ID: MRFR/Pharma/3139-HCR | 85 Pages | Published By Rahul Gotadki on March 2023

Asia Pacific Lignocaine Market Synopsis

The Asia Pacific Lignocaine Market is expected to reach USD 1,137.41 Million by 2030 at 5.90% CAGR during the forecast period 2022-2030. Lidocaine, also known as xylocaine or lignocaine, is a medication used in a spectrum of medical applications such as local anaesthetic, to treat ventricular tachycardia or arrhythmia, and to perform nerve blocks. Inhaled lidocaine is a cough suppressor that reduces cough reflex. Lidocaine’s mechanism of action is blocking sodium channels, thus preventing local neuron signal from reaching the brain. Lidocaine is an antiarrhythmic medication which reduces the contraction of heart.

Common side effects of lidocaine include sleepiness, muscle twitching, confusion, changes in vision, numbness, tingling sensation, vomiting, low blood pressure and an irregular heart rate. It is generally safe to use in pregnancy but patients with liver problems may require a smaller dose. Lidocaine is on the Asia Pacific Health Organization's List of Essential Medicines, and is inexpensive. Adverse effects of lidocaine are tremors, euphoria, hallucinations, bradycardia, arrhythmias, bronchospasm, dyspnea, etc.

The lidocaine sales are suffering from lignocaine market fragmentation, which has put pressure on the price margins. The generics have captured the major market share and the rise of counterfeited products has also restricted the market growth. The other market constrains are low price and adverse side effects of lidocaine use. Market development strategy has been constrained as lidocaine has been around market for many decades. Thus there is presence of huge production capacity which has also put pressure on prices. This has led to large players quitting the market. However, product development in the form of formulation development has been successful as exemplified by inhalation sprays. Moreover the high volume and low value nature of lidocaine has restricted the market to small players.

However, the lignocaine market is extremely stable and a player with efficient production will reflect stable revenues, the presence of large governmental contract market also needs to be tapped. Thus, production and distribution efficiency coupled with product development strategies is expected to be critical factors in the Asia Pacific lidocaine market.

Figure 1 Asia Pacific Lignocaine Market by Applications, 2016 (%)

Segments

The Asia Pacific Lignocaine market has been segmented on the basis of application, formulation and end user.

Based on the application, the lignocaine market has been segmented as local anesthesia, anti-arrhythmic and others.

Based on the formulation, the lignocaine market has been segmented as injectable, topical, inhalation and others.

Based on the end user, the lignocaine market has been segmented as hospitals & clinics, academic and research, and others.

Regional Analysis

The Asia Pacific region accounts for a significant lignocaine market share owing to large population and fast developing and expanding healthcare facilities. Additionally, the large unmet needs of populous countries such as China and India is resulting in greater growth of the Lignocaine market in the regions. The sluggish growth of the developed regions of world also has resulted in transfer of growth of the lignocaine market to the developing markets of Asia Pacific. The lidocaine market is expected to be led by countries such as China and India due to their large populations and large industrial base as compared to other Asia Pacific countries. However the nations of Vietnam, Cambodia, Myanmar, Indonesia etc. are witnessing faster growth as compared to other Asia Pacific countries.

The poorly developed countries are expected to be the fastest growing regions in the Asia Pacific. The larger unmet needs and the faster development of health facilities coupled with the cheaper and essential nature of the lidocaine is driving the market in these regions. The growing application of lidocaine for veterinary use is expected to drive the future market as these countries have large animal population.

Furthermore, concentration of the large low end and low tech companies in the developing countries of this region such as China and India is resulting in excess capacity which needs to be exploited. However the growth in this region can be constrained by the current political conditions, and poor healthcare development.

Key Players in the Asia Pacific Lignocaine Market

Some of the key players profiled in the report are Croma-Pharma GmbH, Cironpharma, Endo Pharmaceuticals, ESBA Laboratories, Sigma-Aldrich, Swati Spentose Pvt. Ltd., Sambria Pharmaceuticals, Pierrel S.p.A., Galen US Inc., Mahendra Chemicals, Iwaki Seiyaku Co., Ltd., Biotechnica Pharma Asia Pacific, Harman Finochem Limited, Endo International, and others.Intended Audience

Asia Pacific Lignocaine treatment manufacturers & suppliers

Research and development (R&D) companies

Hospitals and clinics

Academic institutes and universities

Research Methodology

Sources: Mayo Clinic, Healthline Media, MRFR Analysis

Speak to Analyst Ask for Customization